AHT-102

Primary objectives: To evaluate the safety and tolerability of AHT-102 injection in the treatment of subjects with CLDN18.2-positive advanced solid tumors; To determine the maximum tolerated dose (MTD) and/or recommended dose (RP2D) of AHT-102 injection for Phase II clinical studies. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of AHT-102 injection in the treatment of subjects with CLDN18.2-positive advanced solid tumors; To evaluate the immunogenicity of AHT-102 injection in the treatment of subjects with CLDN18.2-positive advanced solid tumors; To evaluate the preliminary anti-tumor activity of AHT-102 injection in subjects with CLDN18.2-positive advanced solid tumors using the Solid Tumor Efficacy Evaluation Criteria Version 1.1 (RECIST V1.1). Exploratory purpose: Use the immunotherapy efficacy evaluation criteria for solid tumors (iRECIST) to evaluate the preliminary anti-tumor activity of AHT-102 injection in subjects with CLDN18.2-positive advanced solid tumors (iRECIST evaluation is used only after RECISTV1.1 is evaluated as PD); Evaluate the pharmacodynamic (PD) characteristics of AHT-102 injection in the treatment of subjects with CLDN18.2-positive advanced solid tumors; In the dose expansion phase, evaluate the changes in the levels of blood molecular markers in subjects with CLDN18.2-positive advanced solid tumors treated with AHT-102 injection.